Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to NEXGEL's Q4 and full year 2023 earnings conference call. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications, for introductions. Please go ahead. Thank you, operator. Good morning and welcome, everyone, to NEXGEL's Q4 and full year 2023 Earnings Conference Call. I'm joined today by Adam Levy, Chief Executive Officer, and Adam Drapczuk, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties, and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to the press release issued this morning and filed with the SEC on Form 8-K, as well as the company's reports filed periodically with the SEC. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Thank you, Valter. Thank you, everyone, for joining us today to discuss our Q4 and full year 2023 financial and operating results. 2023 was a record year for NEXGEL and transformational in many respects. Over the course of the year and into our current Q1, we have significantly expanded our operational infrastructure, solidified several key strategic partnerships with multi-billion-dollar corporations, and made key strategic investments that collectively have our company prepared for what we believe will be significant growth going forward. For the full year of 2023, we increased revenue by nearly 100% year-over-year to approximately $4.1 million. This year-over-year growth was driven by an increase in both contract manufacturing and branded products of 166% and 52%, respectively. For the Q4, revenue decreased slightly sequentially, mainly due to seasonality in both our contract manufacturing and consumer business. A recurring pattern historically in our branded products has been to see increased sales beginning in February and peaking in Q3. We therefore expected a slight decrease in revenue from Q3 to Q4 and a trend upwards in our current Q1 throughout the remainder of the year, which I will provide more details on shortly. As a reminder, the Q2 of 2023 was our first full quarter of revenue contribution from our joint venture with CG Converting and Packaging in Texas. Segmenting our revenue between contract manufacturing and branded products, in 2023, we are proud to have grown branded product revenue by approximately $427,000, or 52.4%, to $1.24 million. For the Q4 of 2023, branded products revenue was $392,000, an increase of 104.2% year-over-year and 10.1% sequentially. When you exclude Kenkoderm from branded products, the year-over-year growth in the Q4 of 2023 was approximately 45%. Our hero product, SilverSeal, a hospital-grade hydrogel dressing for wounds and burns, continued to drive consumer demand within the OTC wound care market. Today, we have 29 health and beauty products sold direct to consumer. From the ground up, we have built a line of direct-to-consumer health and wellness products that we expect will continue to grow in the foreseeable future year- over- year, with several growth strategies in place, including expansion into Europe and a retail strategy for North America. For the full year, gross margins were 15.1% compared to 12.5% in 2022. As I mentioned earlier, in our branded products, we have several growth opportunities to sell into Europe. To do so, we must be European Medical Device Regulation, or MDR, compliant. Once our facility and operation are fully MDR compliant, we will be able to self-certify all of our Class I Medical Devices, thereby opening up the European market for us. During the Q4 of 2023, we had expenses of approximately $153,000 relating to the process of receiving MDR compliance, such as the inspections, consulting fees, and application fees, which are accounted for in our SG&A. Our final inspection is scheduled for Q2 of this year. Therefore, we expect some further MDR compliance costs in Q1 and some in Q2 as well, totaling approximately an additional $150,000. I would also like to provide insight into how we analyze gross profit margins and where the growth levers are. We look at margins three ways at NEXGEL. First, our branded products we currently sell direct to consumer carry a fairly stable contribution margin of between 20%-25%. There are some efficiencies that should occur as we optimize and scale, but we see this as a stable profit for the company in the coming quarters. Secondly, our converting and packaging operations carry a contribution gross margin of approximately 20%-30% on retail products and 30%-40% on medical device products. We will steadily move towards the higher end of this range as new state-of-the-art automation equipment arrives at the facility and comes online. Additionally, as we have mentioned before, we are already in process with our landlord to expand this facility by approximately doubling the square footage to meet the significant increase in demand we expect going forward. The additional space, along with having three, not one, automated machine lines, will significantly increase our operational efficiency. Lastly, and our biggest growth lever is gel manufacturing in our Pennsylvania facility. While we have grown utilization of this facility as our branded product sales have increased, we are still only operating at approximately 9%-13% capacity. Given that our fixed costs will only increase minimally as we increase production to meet the demand on our significant partnership agreements, once these customers come online and throughput increases, we expect continued improvement in our margins and cash flow. One of these key customers is AbbVie, who provides a major growth driver for our company and an important validation of our hydrogel technology. In October 2023, we executed a supply agreement with AbbVie to be the exclusive supplier of gel pads for their Resonic Rapid Acoustic Pulse device, which is to be used for the improvement in the appearance of cellulite. In December 2021, AbbVie acquired the owner of this technology, Soliton, for $550 million in cash after its RESONIC device demonstrated significant improvement in the appearance of cellulite. After extensive due diligence from AbbVie for many months, our hydrogels were chosen as the exclusive required razor blade to its razor model for each procedure to be done. Our ability to meet the high standards of AbbVie demonstrates the uniqueness of our technology and the fact that a company of their size would select us is something that we are very proud of. Our dialogue with AbbVie to date has been engaging and collaborative as the launch approaches. We speak weekly to ensure that we, as one of the many suppliers on this launch, that it goes off flawlessly. We have said many times that this is AbbVie's launch, not ours. We had targeted mid-2024 for the launch as likely, but it is now looking more like the end of 2024. In Q1, we received a non-refundable $176,000 deposit from AbbVie against their first order. While this is a deposit and not reflected in revenue, the additional capital is certainly helpful. In addition to AbbVie, we have several other important growth drivers for 2024. In December, we announced an important partnership with STADA, a European leader in consumer health, to distribute and commercialize a product line of consumer health OTC products in North America. Our investment in MDR compliance will also bode well for this partnership in Europe and in the future as well. The launch of these products is on schedule as planned for midsummer. Also in December, we acquired Kenkoderm, a privately owned skincare company focused on treating the symptoms of psoriasis. The addition of six new SKUs, which include cream, salt soap, mud soap, shampoo, conditioner, and a multivitamin, perfectly aligned with our health and wellness offering, bringing forth immediate synergy to support optimization of marketing and supply chain operations. In Q4, we recognized one month of revenue for the Kenkoderm product line, and our current Q1 will be our first full quarter of revenue. This product line is profitable and will contribute positively to our financial results in Q1. Cash at December 31, 2023, was $2.7 million as compared to $3.27 million at September 30, 2023, reflecting a $546,500 payment in cash for Kenkoderm paid in Q4. Subsequent to the end of the year, we completed a registered direct offering led by insiders of just over $1 million at attractive terms, and we feel very comfortable with our cash runway. Looking into Q1, we expect revenue of $1.25 million, which reflects the full quarter of revenue from Kenkoderm but does not include the $176,000 deposit from AbbVie discussed earlier, and that will not be booked yet as revenue but rather as a deposit. We also expect margins to be in line with that of the Q4 or slightly improved. We have a lot to be excited about in 2024. I want to thank our entire team for laying the foundation for growth for the future. With that, I would like to turn the call over to our CFO, Adam Drapczuk. Adam? Thank you, Adam. Today, I'll review financial highlights of our Q4 full year 2023 results. For the year ended December 31, 2023, revenue totaled $4.1 million, an increase of $2 million, or 99.7%, as compared to $2 million for the year ended December 31, 2023. The increase in revenue was primarily due to sales growth in contract manufacturing of 166% and branded products 52% year-over-year. For the Q4 of 2023, revenue totaled $1.1 million, an increase of approximately 110% as compared to $524,000 in the Q4 of 2022. Gross profit totaled $619,000 for the year ended December 31, 2023, compared to a gross profit of $256,000 for the year ended December 31, 2023. Gross profit margin for 2023 was approximately 15.2% as compared to gross profit margin of 12.5% for 2022. The increase in the gross profit year-over-year directly correlates to our higher sales. Gross profit for the Q4 of 2023 was $158,000 compared to $36,000 for the same period in 2022. Gross profit margin for the Q4 of 2023 was 14.6%. Cost of revenues increased by $1.7 million, or 93.6%, to $3.5 million for the year ended December 31, 2023, as compared to $1.8 million for the year ended December 31, 2023. The increase in cost of revenues pertains to an increase in materials and finished products and equipment, production, and other expenses. These increases primarily align with the increased revenues. Cost of revenues was $924,000 for the quarter ended December 31, 2023, an increase of $436,000 compared to $488,000 for the quarter ended December 31, 2023. The increase in cost of revenues was attributable to the company's revenue growth. Selling, general, and administrative expenses increased by $756,000, or 23.4%, to $4 million for the year ended December 31, 2023, as compared to $3.2 million for the year ended December 31, 2023. The increase in selling, general, and administrative expenses is primarily attributable to an increase of compensation and benefit expense, advertising, marketing, and Amazon fees, as well as the cost for professional consulting fees. Selling, general, and administrative expenses totaled $1.4 million in the Q4 of 2023 as compared to $778,000 for the same period the prior year. Research and development expenses decreased by $264,000 to $103,000 for the year ended December 31, 2023, from $367,000 for the year ended December 31, 2023. The decrease is due to the completion of development efforts of two proof-of-concept studies for drug delivery candidates utilizing our hydrogel technology. In 2022, the company paid off approximately $3.5 million in convertible notes, reducing interest expense from $1.3 million in 2022 to less than $20,000 as of December 31, 2023. Net loss for the year ended December 31, 2023, was $3.2 million as compared to $4.7 million for the same period the year prior. As Adam mentioned, as of December 31, 2023, the company had $2.7 million in cash and subsequently closed on approximately $1 million registered direct offering led by insiders. As of December 31, 2023, NEXGEL has 5,741,088 shares of common stock outstanding, which increases to 6,227,624 shares of common stock outstanding in Q1. The Q1 increase is primarily a result of the aforementioned registered direct offering. I would now like to open the call for questions. Operator? At this time, if you would like to ask a question, please press star one on your telephone keypad. You may remove yourself at any time by pressing star two. Once again, that is star and one to ask a question. We'll pause just a moment to allow questions to queue. Once again, that is star and one to ask a question. Our first question will come from Bill Odenthal with Kova Capital. Please go ahead. Hey, Adam. Two questions, if you can handle them. One is, when do you expect to be MDR compliant, this year in Europe and, and, and actually start selling product overseas? Hello? Hello? I think, Gary. Yeah. Might be on mute. Yeah. We can hear you now. Oh, I'm sorry, guys. Yeah, can you hear me? That's all right. Yeah. Now I got you. Yeah. So, yeah. Thanks. So, Billy, there's several pre-inspections that we've already gone through. The final inspection is scheduled in Q2, at the end of May. Maybe gets pushed to the first week of June. But at that point, we expect to be MDR compliant. That will allow us to begin to release all of our Class I devices and be self-certified. Some of the Class III, like SilverSeal, might take a little bit longer. We're targeting, you know, the end of the year for clearance on those. But it will start the flow of our products moving out into Europe. And we have a lot of interest from different parties for that market. Tough question, but I'm gonna ask it anyhow. When can we expect the company to start having positive cash flow? Well, as you know, that's, that's one of our primary, motivating, objectives. I would simply say stay tuned. We've obviously had to spend a little bit of money, for some of these, like, MDR, initiatives as well as our expansion. But it is coming. Stay tuned. Okay. Great. Thank you. Thank you. As a reminder, if you would like to ask a question, please press star one at this time. Our next question comes from Kenneth Sherb. Please go ahead. Hi, Adam. Good morning. My question was regarding. Good morning. Net working capital. Are you guys confident that you have enough cash runway to fund these orders? I'm assuming and hoping that these are large orders from AbbVie and STADA. But just, like, looking at your balance sheet, it looks like half your cash is already tied up with or can be used for accounts payable and whatnot. And I'm assuming that there's some long payment terms with AbbVie. So could you provide some clarity on that? Yeah. Actually, the opposite is true. So when I think about concerns for the cash flow, I think about our move into retail and, you know, accounts like these big-box retailers. They're the ones that tend to jerk you around for cash. Our experience has been with these big multinationals so far, and we now, you know, have a relationship with three or four of them, is that they wanna pay you in one day because they all have financing arms. And in fact, I can share with you that we've already been offered a very, very early payment on the deposit. So those companies, for a point or two, are always anxious to pay you as fast as possible. It is the opposite when we go to retail. But for companies like AbbVie, Medtronic, Owens & Minor, they all have super fast payment terms. Okay. That's, that's wonderful to hear. And then my second question was, regarding the Kenkoderm acquisition. Have you guys seen any revenue synergies, with that acquisition, or has it really been accretive? So it's been accretive in that we bought something that was already profitable. We've been able to improve the margins by optimizing some of the advertising. But the true, you know, bonus of, of shall we say, the one plus one equals three of this deal, which is cross-promoting we're waiting for the completion of our new and updated website, which is another infrastructure project we're investing in. We really, at the start, didn't know how successful our consumer products would be. So we need to get that updated, have a good front face. And then and by the way, that project should be completed in early June. And then we'll be launching a lot of these cross-synergies. The one synergy we have seen is that as I've gone to Europe and begun discussing, you know, NEXGEL products for distribution there, there's also considerable interest for Kenkoderm. There's also interest in Kenkoderm at certain retailers here in the U.S. So Kenkoderm is another product in my bag. You probably won't see those deals and/or that revenue until later in the year. But we think those synergies are definitely coming. Wonderful. Thank you. As a reminder, if you would like to ask a question at this time, please press star one on your telephone keypad. We'll pause just a moment to allow additional questions to queue. And again, that's star one to ask a question. And we'll go ahead and take our next question from Naz Rahman with Maxim Group. Please go ahead. Hi. This is my question. Congrats on the progress. See how AbbVie is now planning on launching what looks to be at the end of 2024. Do you think you might see any considerable pre-orders or revenue recognition for, relating to the RESONIC device in 2024, or do you think that would premiere in 2025? Well, no. We're looking at delivery at the end of 2024 according to the latest that we've gotten from them. So we will see some revenue. But obviously, the first full big quarter of revenue is now looking like Q1. But there will definitely. Got it. Be revenue and pre-orders in Q4. Got it. Thank you. So last year, you guys launched your Amblyopia Patch, if I recall correctly, over the summer. Now that you've had several months' worth of data, could you provide some color and metrics on how that launch has gone and if you're seeing any reordering patterns from docs? So we are seeing the short answer is it's going slowly. It is growing. We have seen reorder patterns from the docs that have it. I think I might have talked about this a little bit on the last call. But one of the, you know, issues or errors that we made was the assumption that docs would be interested in a profit margin associated with selling in office. That has turned out not to be the case. In fact, most of the docs said, "Look, this would be a lot easier if we could just send our patients to Amazon." As a result, you will be seeing in the next 10 days the product available on Amazon with the docs able to refer their patients to simply buy it directly from us. This is, A, good for margins. And B, we think will be a much more efficient method of getting the product out there. So again, the answer is it's been growing but slowly. And we're hoping that this change in distribution method will help speed things up. Got it. As far as you're going into retail now, you guys talked about it a little bit. When you plan when you go into retail, is your product offering just gonna include the SilverSeal brand, or do you also plan on including Kenkoderm and also potentially STADA's products? So that's a great question. The idea at retail is you want to go with your hero products, right? Because retail can be a double-edged sword. If you go to retail with the wrong product or too early on a product, you'll get destroyed. You know, you'll end up paying a fortune to get it in there. It won't sell. You'll get returns. They won't pay you. You know, a lot of the cash flow problems that Ken was worried about will begin to occur. So in the beginning, we're gonna limit it to Kenkoderm, certainly has the ability to go in there. It should be a very good product for retail because it is focused and specialized and has strong Amazon sales. SilverSeal, for sure. Hexagels. Those are the types of products we'll start with. And then we'll see from there. Got it. Thank you. My last question is, could you potentially give an update on the status of the 510(k), medical devices, NexDrape and NexDerm? Like, where are you at with those in development? What are your plans for that in 2024? Sure. So we've kind of pushed those a little bit on hold only because there's so many things we can do and the equipment necessary for the extrusion process on there while we now have identified what it is we need. You know, our first our first priority is for the mechanization that will allow us to deliver all the AbbVie products and STADA products, etc. So that's, that's been kind of a shift. But we're also still running experiments on sterilization protocols. And, interestingly enough, it seems like there's another opportunity for us with a cataract surgical drape. So we're still experimenting. We're still developing the product. But, you know, it's really kind of number five on our list of priorities right now just because there's so much for us to do. Got it. Thank you. Thanks for taking my question. Sure. Thank you. As a final reminder, if you would like to ask a question, please press star one at this time. We'll pause a few moments to allow any additional questions to queue. We have no questions in the queue at this time. This will conclude today's NEXGEL Q4 and full-year 2023 earnings conference call. You may disconnect your line at this time. Have a wonderful day.